ORGS vs. SLGL, HUGE, LPCN, LSTA, SNSE, MEIP, SPRB, FBRX, CPIX, and TCRT
Should you be buying Orgenesis stock or one of its competitors? The main competitors of Orgenesis include Sol-Gel Technologies (SLGL), FSD Pharma (HUGE), Lipocine (LPCN), Lisata Therapeutics (LSTA), Sensei Biotherapeutics (SNSE), MEI Pharma (MEIP), Spruce Biosciences (SPRB), Forte Biosciences (FBRX), Cumberland Pharmaceuticals (CPIX), and Alaunos Therapeutics (TCRT). These companies are all part of the "pharmaceutical preparations" industry.
Orgenesis (NASDAQ:ORGS) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, community ranking, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.
Sol-Gel Technologies received 146 more outperform votes than Orgenesis when rated by MarketBeat users. However, 100.00% of users gave Orgenesis an outperform vote while only 63.09% of users gave Sol-Gel Technologies an outperform vote.
Orgenesis has a net margin of -91.25% compared to Sol-Gel Technologies' net margin of -1,331.01%. Sol-Gel Technologies' return on equity of -61.52% beat Orgenesis' return on equity.
Orgenesis has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500. Comparatively, Sol-Gel Technologies has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500.
22.6% of Orgenesis shares are owned by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are owned by institutional investors. 7.1% of Orgenesis shares are owned by company insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Sol-Gel Technologies had 1 more articles in the media than Orgenesis. MarketBeat recorded 3 mentions for Sol-Gel Technologies and 2 mentions for Orgenesis. Sol-Gel Technologies' average media sentiment score of 0.96 beat Orgenesis' score of 0.00 indicating that Sol-Gel Technologies is being referred to more favorably in the news media.
Orgenesis has higher revenue and earnings than Sol-Gel Technologies. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Orgenesis, indicating that it is currently the more affordable of the two stocks.
Sol-Gel Technologies has a consensus target price of $8.00, suggesting a potential upside of 684.31%. Given Sol-Gel Technologies' higher possible upside, analysts clearly believe Sol-Gel Technologies is more favorable than Orgenesis.
Summary
Sol-Gel Technologies beats Orgenesis on 11 of the 18 factors compared between the two stocks.
Get Orgenesis News Delivered to You Automatically
Sign up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ORGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Orgenesis Competitors List
Related Companies and Tools